Discover and read the best of Twitter Threads about #Antibody
Most recents (24)
✨ We're delighted to present a new Special Issue on Human #Bcells!
Guest edited by @BemarkMats, @JoSpencerLab & @Thomas_J_Tull, this collection explores the complexity of #Bcell development & function
Explore the articles below 🧵 & read for free ➡️bit.ly/40O6Onh
1/10
Guest edited by @BemarkMats, @JoSpencerLab & @Thomas_J_Tull, this collection explores the complexity of #Bcell development & function
Explore the articles below 🧵 & read for free ➡️bit.ly/40O6Onh
1/10
As well as #Bcell subtypes in health & inflammatory diseases, this collection also examines aspects of B cell diversity depending on #immunoglobulin isotype & in a microanatomical context
Our guest editors introduce the series in this Editorial 👇 2/10
academic.oup.com/cei/article/21…
Our guest editors introduce the series in this Editorial 👇 2/10
academic.oup.com/cei/article/21…
Rebekah Velounias & @Thomas_J_Tull @KCLImmunoMicro kick off the series papers with a discussion of B cell subset classification & their changes in #inflammatory disease 3/10
academic.oup.com/cei/article/21…
academic.oup.com/cei/article/21…
As we see videos in social media of the first $PACB PacBio Revio to enter the @broadinstitute , with the promise of the long-read $1000/genome in place, what does it look like today to set up a Next-Generation Sequencing factory/institute?
There have been many of these institutes come and go, and probably the @broadinstitute (Cambridge, US) and the @sangerinstitute (Cambridge, UK) are the two referents in historical terms and in their magnitude of achievements in #genomics. So if we take them as an example, what do
In #JPM2023 news, $ABSI Absci presented on Thursday 12, 2023. Also following the trend of asking AI what they should do, the company's Chief Morale Officer was put to the task of discovering biologics on a computer. Well, DALL-E's interpretation of that was on a slide.
Absci has a slide about the "old paradigm" of drug discovery, focusing on #Antibody discovery. Either phages or mice are used to generate antibodies that bind to targets, and a process of optimization of affinity, toxicity and developability (how to produce large amounts of it)
takes place, until the antibody candidate is decided. Absci rates this at a less than <5% success rate, which is definitely in the ballpark if we take into account phage display for therapeutic antibodies as part of the denominator.
In #JPM2023 news, a quick round of companies that presented on Monday, but have little overlap with the list of companies I track and the list of fields I post about.
$T Thermo Fisher has 1 slide mentioning NGS, with their Oncomine Dx Express Test and Reporter Dx Software.
In #JPM2023 news, $TWST Twist Biosciences also presented on Monday, and here are some highlights of their presentation: first slide is the obligatory comparison between Twist 1M oligos per chip technology compared to the plate-based methods.
Their #SynBio revenue is still growing, but proportionally less than the #NextGenerationSequencing segment and the #Biopharma segments.
They have a new factory which they expect to start shipping products in January 2023 (now!) and would mean doubling up their current capacity.
In an Invited Editorial in @JAMAOnc today, my colleagues & I call for health systems to develop “Comprehensive #Pandemic Support Programs” for their most vulnerable patients.
These are our Top 10 Tips!
THREAD 🧵
jamanetwork.com/journals/jamao…
These are our Top 10 Tips!
THREAD 🧵
jamanetwork.com/journals/jamao…
Tip #1: Health systems should explain to all patients that #COVIDisAirborne and is best avoided through multi-layered mitigation.
Tip #2: Health systems should prioritize getting the most vulnerable patients vaccinated & boosted.
Offer #vaccines on-site w/the SAFEST options.
Vulnerable patients want highly-ventilated or outdoor options & high-quality (e.g., N95) masks for safety. Make it happen.
Offer #vaccines on-site w/the SAFEST options.
Vulnerable patients want highly-ventilated or outdoor options & high-quality (e.g., N95) masks for safety. Make it happen.
For anyone doing #flowcytometry, would you like to have a new protocol that reduces your #antibody costs by ~10-fold and also gives you higher quality data, with better signal-to-noise ratio?
Yes? Then read work by @olivertburton and @CarlyEWhyte. 1/6
…rentprotocols.onlinelibrary.wiley.com/doi/epdf/10.10…
Yes? Then read work by @olivertburton and @CarlyEWhyte. 1/6
…rentprotocols.onlinelibrary.wiley.com/doi/epdf/10.10…
Bottom-line-up-front: stain overnight. Antibody staining is sensitive to both dilution and time, so a titration that gives crummy staining in 30' can actually give beautiful staining overnight. The best part is, that lower dilution gives less background, for better separation 2/6
You can see this quite clearly with even tricky staining, like #Foxp3 and #cytokines. The overnight stain gives a stronger positive signal without increasing the background at all. Plus your cells are ready in the morning, when the cytometer is free, rather than 8pm at night! 3/6
1) Welcome to an #accredited #tweetorial on a unique emerging (in Ph3 now) option for specifically reversing the #antiplatelet effects of #ticagrelor: it's #bentracimab. Expert faculty is antithrombotic agent reversal guru @md_pollack of @UMMCnews, working to create #AHealthierMS
2) This program is intended for #healthcare professionals and is supported by an educational grant from PhaseBio Pharmaceuticals. Faculty disclosures are listed at cardiometabolic-ce.com/disclosures/, and prior programs are available for 🆓CE/#CME credit at cardiometabolic-ce.com.
3) It is an unfortunate fact of life that one cannot prescribe #anticoagulant or #antiplatelet (together, #antithrombotic) therapy without increasing a patient's #bleedingrisk. That is why it should be an individualized risk:benefit decision, ideally . . .
I want to put this study on everyone's radar b/c I think it's a genuinely cool opportunity for people/patients to get high-quality data on their #SARS-C0V-2 #immune status over time👇 (I have no financial ties to the company).
2/ To be more clear about what the study involves, the @serimmune team will assess each subjects’ individual immune response to SARS-CoV-2 from both natural #infection and #vaccination for up to 5 years.
3/ If you register for the study, Serimmune will send you a sample collection kit that allows you to collect your blood at home. Then you simply mail the sample to their lab using the pre-paid envelope provided.
I'm excited to share with you our recent @biorxivpreprint where we demonstrate that @vaxart mucosal Ad5 #SARSCoV2 vaccines not only protected against disease but also reduced transmission after post-#vaccination #SARSCoV2 infection in a hamster model. biorxiv.org/content/10.110… A🧵/
If you follow me, you are well aware of my obsession w/ #mucosalimmunity.😂Protection generated at mucosal surfaces is at the crux of one of the biggest questions we need to answer during this unique phase of the #pandemic - How do we decrease #SARSCoV2 #transmission to others.
Considering most of the world is unimmunized (including most kids <12), the possibility that a vaccinated individual with a post-vaccination infection (aka #breakthrough) can spread #SARSCoV2 is a public health risk. We need #transmissionblocking strategies.
The latest #antibody study from @ONS is out, and shows continued increases in all four countries, with 🏴 now topping 90%. 👏👏
E🔼from 86.6% to 89.8%
W🔼from 88.7% to 91.8%
NI🔼from 85.4% to 87.2%
S🔼from 79.1% to 84.7%
Here's a visual summary of the last three reports.
1/
E🔼from 86.6% to 89.8%
W🔼from 88.7% to 91.8%
NI🔼from 85.4% to 87.2%
S🔼from 79.1% to 84.7%
Here's a visual summary of the last three reports.
1/
Note that although the reports are fortnightly, the last one moved the data on three weeks, this one only one week. So that's one reason why the increases are lower. Also, as we get closer to 100%, there will be a natural limit to the increase possible.
2/
2/
You can see that in the youngest age groups, the level of antibodies is around twice the vaccination coverage, with naturally acquired antibodies making up the difference. (ie they have had COVID at some stage.)
3/
3/
In an @AllofUsResearch study, #antibody testing of more than 24K stored blood samples given by participants in Jan.-Mar. 2020 provided evidence of #COVID19 infections in five states (IL, MA, MS, PA, & WI) earlier than those states’ first reported cases. (1/4)
We found a total of 9 samples w/ antibodies against SARS-CoV-2, collected as early as Jan. 7 and 8, 2020. Since antibodies take a few weeks to be detected after infection, this adds to evidence that the virus was present in the U.S. in late Dec. 2019. (2/4)
#COVID #Immunity #Vaccination #AntibodyTitres are not necessarily an indicator of COVID immunity. A lot of people are posting messages worried about not demonstrating antibodies post-vaccination. This is a myth that needs to be addressed. Follow this thread......
There are various types of antibody tests, directed against specific components of the virus. Just bcoz antibody to 1 component is absent, doesn't imply lack of the immunity, coz we may have other COVID neutralising antibodies we haven't been tested for!
+ there is something called cell-mediated immunity which doesn’t show up in antibody tests. Moreover, antibodies may be present, in memory cells in the bone marrow and not in the circulating blood. They may only be recruited to fight when exposed to the virus!
A metal ion orients SARS-CoV-2 mRNA to ensure accurate 2′-O methylation of its first nucleotide
» doi.org/10.1038/s41467…
The #SARSCoV2 #coronavirus is able to utilize the changes in metal ion concentrations to disguise itself in the human host body thus evading immune responses.
» doi.org/10.1038/s41467…
The #SARSCoV2 #coronavirus is able to utilize the changes in metal ion concentrations to disguise itself in the human host body thus evading immune responses.
Efficacy of #clarithromycin on #COVID19 pneumonia without oxygen administration; protocol for multicenter, open-label, randomized-controlled, 3-armed parallel group comparison, exploratory trial #CAMECOVID
» doi.org/10.1101/2021.0…
Japan Registry of Clinical Trials jRCTs071210011
» doi.org/10.1101/2021.0…
Japan Registry of Clinical Trials jRCTs071210011
The influence of #HLA genotype on the severity of #COVID19 infection
» doi.org/10.1111/tan.14…
A genetic link has been discovered explaining why some people catch #Covid but don't get sick. The gene is found three times as often in people who are #asymptomatic.
» doi.org/10.1111/tan.14…
A genetic link has been discovered explaining why some people catch #Covid but don't get sick. The gene is found three times as often in people who are #asymptomatic.
🔝5 Concerns about #SARSCoV2 #Biology: A Call to Pause, Deliberate, and Revise Policy─This review is intended both as a basic resource and to initiate an open and critical dialog about SARS-CoV-2 biology for an independent and public call to action. jjcouey.medium.com/5-concerns-abo…
Structural basis of ribosomal #frameshifting during translation of the #SARSCoV2 #RNA #genome
» doi.org/10.1126/scienc…
A unique feature of the SARS-CoV-2 genome controls protein synthesis and presents an "Achilles heel" of the virus.
» doi.org/10.1126/scienc…
A unique feature of the SARS-CoV-2 genome controls protein synthesis and presents an "Achilles heel" of the virus.
Brainstem neuropathology in two cases of #COVID19: #SARSCoV2 trafficking between #brain and #lung
» doi.org/10.1007/s00415…
Neuropathologic evidence strongly suggests that the pathophysiology of COVID-19 related respiratory failure includes a neurogenic component.
» doi.org/10.1007/s00415…
Neuropathologic evidence strongly suggests that the pathophysiology of COVID-19 related respiratory failure includes a neurogenic component.
In the latest issue! Be sure to explore this exciting research about #SARSCoV2 variants and their #escape from #immune response
bit.ly/3e2QxoP
For all @CellPressNews #coronavirus research and commentary, visit cell.com/2019-nCOV
#COVID19
🔽🔽🔽
bit.ly/3e2QxoP
For all @CellPressNews #coronavirus research and commentary, visit cell.com/2019-nCOV
#COVID19
🔽🔽🔽
Mutations in the #SARSCoV2 spike #protein result in tighter binding to the #ACE2 receptor and allow escape from monoclonal #antibody neutralization. Online now! @UniofOxford
bit.ly/3nzukSI
bit.ly/3nzukSI
The 501Y.V2 #variant of #SARSCoV2 exhibits resistance to neutralization from monoclonal #antibodies and sera from convalescent as well as #immunized individuals
bit.ly/3xxMrNe
bit.ly/3xxMrNe
First Dose!
I'm very excited to be joining #GenXZeneca . Even though it took a bit to get an appointment, the process itself was super fast and painless.
#FirstShotOffered
I'm very excited to be joining #GenXZeneca . Even though it took a bit to get an appointment, the process itself was super fast and painless.
#FirstShotOffered
This week also marks the conclusion of the undergraduate immunology course I run. As getting vaccinated is basically a live-demo summary of the entire course, I thought I'd celebrate by live-tweeting my immune response to the vaccine.
#Nerdy , but fun!
#Nerdy , but fun!
(I'm not sure how many of my students would agree about the "fun" part, but I doubt any are on twitter anyway and so they get out of this impromptu lab component).
Let the #LiveTweet begin!
Let the #LiveTweet begin!
Reducing #COVID19 #Airborne #Transmission Risks on #PublicTransportation Buses
» doi.org/10.1101/2021.0…
Wearing of #facemasks reduced the overall particle count released into the bus by an average of 50%, the dispersion distance by several feet and #aerosol particles by 84.36%.
» doi.org/10.1101/2021.0…
Wearing of #facemasks reduced the overall particle count released into the bus by an average of 50%, the dispersion distance by several feet and #aerosol particles by 84.36%.
🔝#SARSCoV2 Infects Human Engineered Heart Tissues and Models COVID-19 Myocarditis
» doi.org/10.1016/j.jacb…
#COVID19 can kill heart muscle cells, interfere with contraction. Details of how #coronavirus infects #heart: models of tissue damage may help develop potential therapies.
» doi.org/10.1016/j.jacb…
#COVID19 can kill heart muscle cells, interfere with contraction. Details of how #coronavirus infects #heart: models of tissue damage may help develop potential therapies.
High-content screening of coronavirus genes for innate immune suppression reveals enhanced potency of SARS-CoV-2 proteins
» doi.org/10.1101/2021.0…
196 protein products of seven coronaviruses: the genes encoded by #SARSCoV2 are generally more potent immune suppressors than others
» doi.org/10.1101/2021.0…
196 protein products of seven coronaviruses: the genes encoded by #SARSCoV2 are generally more potent immune suppressors than others
#Plasma from recovered #COVID19 patients with high levels of #antibodies appeared to delay / stop progression of illness in mildly ill older adults infected with #SARSCoV2, a study published in @NEJM concluded. 🧵nejm.org/doi/full/10.10…
Researchers at Fundacion INFANT in Buenos Aires, #Argentina, led the small randomized, controlled, double-blind #clinicaltrial of the effects of infusing #convalescent #plasma in 160 older adults within 72 hours of symptom onset, half of whom received the treatment.
The patients were either 75 years and older with or without underlying illnesses, or 65 to 74 years with at least one underlying condition. The trial was stopped early because #COVID19 cases substantially declined in #BuenosAires, precluding continued recruitment.
#Germany #Sachsen #Dresden / #Leipzig #Coronavirus #Antibody
Pharmacies in Saxony may in future sell the coronavirus antibody test "AProof" freely. This was announced by the Ministry of Social Affairs. The test developed in Leipzig was presented three and a half weeks ago.
Pharmacies in Saxony may in future sell the coronavirus antibody test "AProof" freely. This was announced by the Ministry of Social Affairs. The test developed in Leipzig was presented three and a half weeks ago.
In principle, the development of an antibody test should be rated positively, said Health Minister Petra Köpping according to the announcement. However, the regional directorate of Saxony had to evaluate the test.
It is important that medical laypeople can safely handle the antibody test. It is therefore necessary for pharmacists to inform the buyer during the consultation.
The test works like this:
The test works like this:
1/ The next hot-button issue in #COVID19 debates: the relative importance of #antibodies versus T cells in #COVID_19 immune response.
(If you're thinking this should be an obscure, wonky, data-driven debate, I have one word for you: hydroxychloroquine.)
(If you're thinking this should be an obscure, wonky, data-driven debate, I have one word for you: hydroxychloroquine.)
2/ Some background. Antibodies are not the only possible source of #COVID19 immunity.
Or as this interesting @NatGeo article puts it, "antibodies might not be telling the whole story when it comes to #Covid_19 immunity."
on.natgeo.com/2DpoH6V #COVID
Or as this interesting @NatGeo article puts it, "antibodies might not be telling the whole story when it comes to #Covid_19 immunity."
on.natgeo.com/2DpoH6V #COVID
3/ Dr. Soo Aleman of Sweden tested patients who previously tested positive for #COVID19, as well as their close contacts. She found that hospitalized patients had strong antibody and T cell responses to #COVID_19 -- no surprise there.
#COVID #coronavirus
#COVID #coronavirus
Lots of talk about “skipping the phase III” trials of #COVID19 #vaccines and going straight to widespread vaccination.
Here’s a not-so-brief thread on why that’s a terrible idea.
1/
Here’s a not-so-brief thread on why that’s a terrible idea.
1/
Ethical considerations aside, there are several reasons we *need* phase 3 trials as part of a developing COVID vaccines:
* Prove Efficacy
* Ensure Safety
* Conserve Limited resources
* Preserve Public confidence
2/
* Prove Efficacy
* Ensure Safety
* Conserve Limited resources
* Preserve Public confidence
2/
Efficacy
Despite efforts to develop vaccines against other coronaviruses (SARS, MERS) we haven’t yet succeeded
Against SARS-CoV2 we are trying a myriad of strategies: mRNA, recombinant, viral vectors, inactivated, etc. We hope one will succeed, but we don’t yet know which one
3/
Despite efforts to develop vaccines against other coronaviruses (SARS, MERS) we haven’t yet succeeded
Against SARS-CoV2 we are trying a myriad of strategies: mRNA, recombinant, viral vectors, inactivated, etc. We hope one will succeed, but we don’t yet know which one
3/
Hmm. I'm aware that authors don't always set their own headline, but this one's actually misleading.
If anything, #COVID19 will likely become like a '#FifthFlu', i.e. a seasonal killer - not MERS or SARS, bur *far* less benign than the common cold...
unherd.com/2020/07/why-co…
If anything, #COVID19 will likely become like a '#FifthFlu', i.e. a seasonal killer - not MERS or SARS, bur *far* less benign than the common cold...
unherd.com/2020/07/why-co…
As @TomChivers points out, with so many publications and so much amplification, it can be difficult to work out what's going on.
There's encouraging news on the #vaccine front, with provisos: of which KCL's #antibody study is one:
There's encouraging news on the #vaccine front, with provisos: of which KCL's #antibody study is one:
(01/31) The late film critic @ebertchicago was not a huge fan of @rolandemmerich’s “Independence Day”. His review of the larger-than-life, schmaltzy blockbuster noted that it was little other than “silly summer fun”, which was reluctant to “slow down for the small details”.
(02/31) ‘Not slowing down’ is very much part of the modus operandi of blogger, hat model and occasional-#PrimeMinister Dominic Cummings. Particularly when maximising the fuel efficiency of the vehicle transporting his symptomatic family to medical facilities in Northern England.
(03/31) Cummings favours haste, brevity and a broad-brush approach over ‘the small details’. This is perhaps best demonstrated by his relentless promotion of catchy-yet-meaningless slogans, such as #StayAlert, #GetBrexitDone and #ConsiderTheMatterClosed.
